Related Experiment Video
Updated: Apr 19, 2026

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
Published on: February 22, 2019
Sphingosine-1-phosphate Receptor Agonism Reduces Bordetella pertussis-mediated Lung Pathology
Ciaran Skerry1, Karen Scanlon1, Hugh Rosen2
1Department of Microbiology and Immunology, University of Maryland Medical School, Baltimore.
Abstract:
Recent pertussis resurgence represents a major public health concern. Currently, there are no effective treatments for critical pertussis in infants. Recent data have demonstrated the potential of sphingosine-1-phosphate receptor (S1PR) agonism in the treatment of infectious diseases. We used the murine Bordetella pertussis model to test the hypothesis that treatment with S1PR agonist AAL-R reduces pulmonary inflammation during infection. AAL-R treatment resulted in reduced expression of inflammatory cytokines and chemokines and attenuated lung pathology in infected mice. These results demonstrate a role for sphingosine-1-phosphate (S1P) signaling in B. pertussis-mediated pathology and highlight the possibility of host-targeted therapy for pertussis.
Insights
A new study shows sphingosine-1-phosphate receptor (S1PR) agonist AAL-R can reduce lung inflammation in infant mice with pertussis. This suggests a potential host-targeted therapy for this serious bacterial infection.
Area of Science:
- Immunology
- Microbiology
- Pharmacology
Background:
- Pertussis (whooping cough) is a growing public health issue, particularly for infants.
- Existing treatments for severe pertussis in infants are lacking.
- Sphingosine-1-phosphate receptor (S1PR) agonists show promise for treating infectious diseases.
Purpose of the Study:
- To investigate if S1PR agonist AAL-R can reduce lung inflammation in a mouse model of Bordetella pertussis infection.
- To explore the potential of host-targeted therapies for pertussis.
Main Methods:
- Utilized a murine model of Bordetella pertussis infection.
- Administered S1PR agonist AAL-R to infected mice.
- Assessed lung pathology and expression of inflammatory cytokines and chemokines.
Main Results:
- AAL-R treatment significantly reduced inflammatory cytokine and chemokine expression in the lungs.
- Attenuated lung pathology was observed in AAL-R treated mice.
- Demonstrated a role for sphingosine-1-phosphate (S1P) signaling in pertussis pathology.
Conclusions:
- S1PR agonism with AAL-R shows therapeutic potential for reducing inflammation in pertussis.
- Highlights the possibility of developing host-targeted treatments for pertussis.
- Further research into S1P signaling pathways could lead to novel pertussis therapies.
Related Concept Videos
Regulation of Bacterial Virulence
GPCRs Regulate Adenylyl Cylase Activity
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Gene Regulation in Microbial Communities: Quorum Sensing
Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...

